Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation Indian Medical PG Practice Questions and MCQs

Question 221: Which recent oral direct thrombin inhibitor can be used for the prevention of stroke?

A. Dabigatran (Correct Answer)
B. Ximelagatran
C. Lepirudin
D. Saxagliptin

Explanation: **Explanation:** **Dabigatran** is the correct answer as it is a potent, competitive, and reversible **Direct Thrombin Inhibitor (DTI)**. Unlike older anticoagulants, it is administered orally as a prodrug (Dabigatran etexilate). It directly binds to the active site of both free and clot-bound thrombin (Factor IIa), preventing the conversion of fibrinogen to fibrin. It is FDA-approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. **Analysis of Incorrect Options:** * **Ximelagatran (B):** This was the first oral DTI developed, but it was withdrawn globally shortly after its release due to severe **hepatotoxicity** (elevation of liver enzymes). * **Lepirudin (C):** While this is a direct thrombin inhibitor (a recombinant derivative of hirudin), it is administered **parenterally** (IV), not orally. It was primarily used for Heparin-Induced Thrombocytopenia (HIT) but has been largely discontinued. * **Saxagliptin (D):** This is a **DPP-4 inhibitor** used in the management of Type 2 Diabetes Mellitus; it has no anticoagulant properties. **High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** The specific reversal agent for Dabigatran is **Idarucizumab** (a humanized monoclonal antibody fragment). * **Monitoring:** Unlike Warfarin, routine INR monitoring is not required for Dabigatran. However, it can prolong aPTT, ECT (Ecarin Clotting Time), and TT (Thrombin Time). * **Excretion:** It is primarily eliminated by the **kidneys**; thus, dose adjustment or avoidance is necessary in severe renal impairment. * **Comparison:** Do not confuse "Gatrans" (Direct Thrombin/IIa inhibitors) with "Xabans" (Direct Factor Xa inhibitors like Rivaroxaban and Apixaban).

Question 222: A patient has subclinical folate deficiency. Which of the following drugs cannot precipitate megaloblastic anemia in this patient?

A. Alcohol
B. Metformin
C. Proguanil
D. Chloroquine (Correct Answer)

Explanation: **Explanation:** The correct answer is **Chloroquine**. To understand this, we must distinguish between drugs that interfere with folate metabolism and those that do not. **Why Chloroquine is the Correct Answer:** Chloroquine is an aminoquinoline used primarily for malaria and rheumatoid arthritis. Unlike many other antimicrobials, it **does not inhibit the dihydrofolate reductase (DHFR) enzyme** nor does it interfere with the absorption or utilization of Vitamin B12 or Folic acid. Therefore, it does not precipitate megaloblastic anemia, even in patients with borderline folate levels. **Analysis of Incorrect Options:** * **Alcohol:** Chronic alcohol consumption is a leading cause of folate deficiency. It interferes with folate absorption in the jejunum, impairs its storage in the liver, and increases renal excretion. * **Metformin:** This first-line antidiabetic drug is well-known to cause **Vitamin B12 deficiency** by interfering with calcium-dependent absorption of the B12-intrinsic factor complex in the terminal ileum. Long-term use can lead to megaloblastic anemia. * **Proguanil:** This is an antimalarial biguanide that acts as a **DHFR inhibitor**. By preventing the conversion of dihydrofolate to tetrahydrofolate (the active form), it directly impairs DNA synthesis, potentially triggering megaloblastic changes in folate-deficient individuals. **High-Yield Clinical Pearls for NEET-PG:** * **DHFR Inhibitors (The "M-P-T" Rule):** **M**ethotrexate, **P**yrimethamine, **P**roguanil, and **T**rimethoprim are classic triggers for megaloblastic anemia. * **Phenytoin:** Also causes folate deficiency by inhibiting the enzyme *folate conjugase* in the gut. * **Leucovorin Rescue:** Folinic acid (Leucovorin) is used to bypass DHFR inhibition caused by Methotrexate, whereas folic acid itself would be ineffective.

Question 223: Warfarin anticoagulants inhibit which of the following coagulation factors?

A. II, V, VII, IX
B. II, VII, IX, X (Correct Answer)
C. II, V, IX, X
D. II, IX, X, XIII

Explanation: **Explanation:** **Mechanism of Action:** Warfarin is a vitamin K antagonist. It acts by inhibiting the enzyme **Vitamin K Epoxide Reductase (VKOR)**. This enzyme is responsible for converting inactive vitamin K epoxide back into its active form (hydroquinone). Active vitamin K is a necessary cofactor for the enzyme **gamma-glutamyl carboxylase**, which performs the post-translational carboxylation of glutamic acid residues on specific clotting factors. This carboxylation is essential for these factors to bind calcium and phospholipid surfaces, making them functionally active. **Why Option B is Correct:** The specific clotting factors that require this vitamin K-dependent carboxylation are **Factors II (Prothrombin), VII, IX, and X**, as well as the endogenous anticoagulants **Protein C and Protein S**. Therefore, Warfarin effectively inhibits the synthesis of functional versions of these four factors. **Analysis of Incorrect Options:** * **Options A & C:** Include **Factor V**. Factor V is a protein cofactor synthesized in the liver but is *not* vitamin K-dependent. * **Option D:** Includes **Factor XIII** (Fibrin Stabilizing Factor). Factor XIII is a transglutaminase that cross-links fibrin but does not require vitamin K for its synthesis. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** Warfarin therapy is monitored using **PT (Prothrombin Time)** and **INR (International Normalized Ratio)**. * **Half-life:** Factor VII has the shortest half-life (~6 hours), while Factor II has the longest (~60 hours). * **Warfarin-Induced Skin Necrosis:** This occurs due to the rapid depletion of Protein C (short half-life), leading to a transient hypercoagulable state before the procoagulant factors are fully depleted. * **Teratogenicity:** Warfarin is contraindicated in pregnancy (causes Fetal Warfarin Syndrome/Chondrodysplasia punctata); Heparin is the preferred anticoagulant. * **Antidote:** For immediate reversal, use **Fresh Frozen Plasma (FFP)** or Prothrombin Complex Concentrate (PCC). For non-emergency reversal, use **Vitamin K1 (Phytonadione)**.

Question 224: All of the following are seen with heparin therapy except?

A. Skin necrosis (Correct Answer)
B. Thrombosis and thrombocytopenia
C. Osteoporosis
D. Alopecia

Explanation: ### Explanation The correct answer is **A. Skin necrosis**. While skin necrosis is a classic dermatological complication of anticoagulant therapy, it is characteristically associated with **Warfarin**, not Heparin. Warfarin-induced skin necrosis occurs due to a rapid decline in Protein C levels (which has a short half-life), leading to a transient hypercoagulable state and microvascular thrombosis in the skin. **Analysis of Options:** * **Thrombosis and thrombocytopenia (Option B):** These are the hallmarks of **Heparin-Induced Thrombocytopenia (HIT) Type II**. This is an immune-mediated reaction where IgG antibodies form against the Heparin-Platelet Factor 4 (PF4) complex. Paradoxically, this leads to platelet activation and life-threatening arterial or venous **thrombosis**. * **Osteoporosis (Option C):** Long-term heparin therapy (usually >3 months) can lead to decreased bone density and spontaneous fractures. Heparin increases osteoclast activity and decreases osteoblast formation. * **Alopecia (Option D):** Transient hair loss is a documented, though less common, side effect of heparin therapy, occurring weeks after the initiation of treatment. **High-Yield Clinical Pearls for NEET-PG:** 1. **Antidote:** The specific antagonist for Heparin is **Protamine Zinc Sulfate** (1 mg neutralizes 100 units of heparin). 2. **Monitoring:** Unfractionated Heparin (UFH) is monitored using **aPTT**, whereas Low Molecular Weight Heparin (LMWH) usually does not require monitoring (except in pregnancy or renal failure, where **Factor Xa levels** are checked). 3. **Hyperkalemia:** Heparin can cause hyperkalemia by inhibiting aldosterone synthesis in the adrenal glands. 4. **HIT Management:** If HIT is suspected, stop all heparin immediately and switch to a direct thrombin inhibitor like **Argatroban** or **Lepirudin**.

Question 225: Alteplase differs from streptokinase in which of the following ways?

A. It has a longer duration of action.
B. It is derived from human kidney cells.
C. It is less expensive.
D. It activates plasminogen that is bound to fibrin. (Correct Answer)

Explanation: **Explanation:** The core difference between Alteplase and Streptokinase lies in their **fibrin specificity**. **1. Why Option D is Correct:** Alteplase is a recombinant **Tissue Plasminogen Activator (t-PA)**. It is "fibrin-selective," meaning it preferentially binds to plasminogen that is already bound to a fibrin clot. This localized activation converts plasminogen to plasmin specifically at the site of the thrombus, minimizing systemic proteolysis. In contrast, Streptokinase is a non-specific activator that converts both circulating and clot-bound plasminogen, leading to a "systemic lytic state." **2. Why the Other Options are Incorrect:** * **Option A:** Alteplase has a very **short half-life** (~5 minutes) and usually requires a continuous infusion, whereas Streptokinase has a longer duration of action. * **Option B:** Alteplase is produced using **recombinant DNA technology** (originally derived from human melanoma cells, not kidney cells). Urokinase is the agent traditionally associated with human kidney cell cultures. * **Option C:** Alteplase is significantly **more expensive** than Streptokinase due to the complex recombinant manufacturing process. **3. High-Yield Clinical Pearls for NEET-PG:** * **Antigenicity:** Streptokinase is derived from *Beta-hemolytic Streptococci* and is **antigenic**. It can cause anaphylaxis and cannot be reused within 6–12 months due to neutralizing antibodies. Alteplase is non-antigenic. * **Mechanism:** Streptokinase does not have intrinsic enzymatic activity; it forms a 1:1 complex with plasminogen to activate it. Alteplase is a direct protease. * **Drug of Choice:** Due to its clot selectivity, Alteplase (or its derivatives like Tenecteplase) is preferred in the management of STEMI, acute ischemic stroke, and massive pulmonary embolism.

Question 226: Which of the following drugs is recommended for the treatment of Heparin Induced thrombocytopenia?

A. Abciximab
B. Lepirudin (Correct Answer)
C. Warfarin
D. Alteplase

Explanation: **Explanation:** **Heparin-Induced Thrombocytopenia (HIT)** is a prothrombotic immune-mediated reaction caused by IgG antibodies against the Heparin-Platelet Factor 4 (PF4) complex. This leads to massive platelet activation and a high risk of venous and arterial thrombosis. **Why Lepirudin is Correct:** The management of HIT requires the immediate cessation of all heparin products and the initiation of a non-heparin anticoagulant. **Lepirudin** is a recombinant derivative of hirudin and acts as a **Direct Thrombin Inhibitor (DTI)**. Unlike heparin, DTIs do not require Antithrombin III for activity and do not cross-react with HIT antibodies, making them the drug of choice for maintaining anticoagulation in HIT patients. **Why Other Options are Incorrect:** * **Abciximab:** This is a GP IIb/IIIa receptor antagonist used as an antiplatelet agent. It does not address the thrombin generation central to HIT and can itself cause drug-induced thrombocytopenia. * **Warfarin:** Warfarin is **contraindicated** in the acute phase of HIT. It inhibits Protein C and S, potentially worsening the hypercoagulable state and leading to **venous limb gangrene**. It should only be started after the platelet count has recovered. * **Alteplase:** This is a fibrinolytic (tPA) used for thrombolysis in acute MI or stroke. It is not an anticoagulant and does not treat the underlying mechanism of HIT. **High-Yield Clinical Pearls for NEET-PG:** * **Alternative DTIs:** Argatroban (preferred in renal failure) and Bivalirudin are also used for HIT. * **Lepirudin Monitoring:** Monitored using **aPTT**. It is primarily excreted by the kidneys (caution in renal impairment). * **HIT Type II:** This is the "true" HIT (immune-mediated), typically occurring 5–10 days after starting heparin, characterized by a >50% drop in platelet count.

Question 227: All of the following are true about heparin except:

A. Its antidote is protamine sulfate
B. It can only be administered in vivo (Correct Answer)
C. It cannot be given orally
D. It increases APTT

Explanation: The correct answer is B, as heparin is effective both in vivo (inside the body) and in vitro (outside the body). This is a high-yield distinction in pharmacology. 1. Why Option B is the correct "Except" choice: Heparin acts by activating Antithrombin III, which then inactivates clotting factors like Thrombin (IIa) and Factor Xa [1, 2, 3]. Since Antithrombin III is present in both circulating blood and collected blood samples, heparin can prevent clotting in test tubes, blood bags, and dialysis circuits. In contrast, oral anticoagulants like Warfarin act by inhibiting the synthesis of clotting factors in the liver; therefore, Warfarin works only in vivo. 2. Analysis of other options: * Option A: Protamine sulfate is the specific antidote for heparin [1, 3]. It is a strongly basic protein that neutralizes the acidic heparin molecule through ionic bonding (chemical antagonism). * Option C: Heparin is a large, highly ionized mucopolysaccharide [1]. It is not absorbed through the gastrointestinal mucosa and is degraded by gastric acid, making oral administration impossible. It must be given parenterally (IV or SC). * Option D: Heparin primarily affects the intrinsic and common pathways [3]. Therefore, the Activated Partial Thromboplastin Time (APTT) is the standard clinical test used to monitor its therapeutic efficacy. Clinical Pearls for NEET-PG: * Mechanism: Indirect thrombin inhibitor (requires Antithrombin III) [1, 2, 3]. * Safe in Pregnancy: Heparin does not cross the placenta (unlike Warfarin), making it the anticoagulant of choice during pregnancy. * Side Effects: Most common is bleeding; most unique is Heparin-Induced Thrombocytopenia (HIT) [3] and osteoporosis (on long-term use). * LMWH vs. UFH: Low Molecular Weight Heparin (e.g., Enoxaparin) primarily inhibits Factor Xa [1, 3] and does not require routine APTT monitoring.

Question 228: All the following drugs are used for thrombo prophylaxis except?

A. Heparin
B. Warfarin
C. Aspirin
D. Anti thrombin (Correct Answer)

Explanation: **Explanation:** The core concept behind this question is the distinction between **prophylactic drugs** (which inhibit clotting factors or platelet aggregation) and **replacement therapy** for a deficiency. **Why Antithrombin is the Correct Answer:** Antithrombin (specifically Antithrombin III) is a natural anticoagulant protein produced by the body [2]. In clinical practice, Antithrombin III concentrates are used as **replacement therapy** in patients with hereditary antithrombin deficiency, particularly during high-risk periods like surgery or childbirth. It is **not** used as a standard pharmacological agent for routine thromboprophylaxis in the general population. Furthermore, heparin requires antithrombin to work; if a patient is "heparin resistant," it often indicates an underlying antithrombin deficiency. **Analysis of Incorrect Options:** * **Heparin (A):** A classic parenteral anticoagulant [3]. Low-dose Unfractionated Heparin (UFH) or Low Molecular Weight Heparin (LMWH) are the gold standards for prophylaxis against Deep Vein Thrombosis (DVT) in surgical and immobilized patients [4]. * **Warfarin (B):** An oral vitamin K antagonist used for long-term thromboprophylaxis in patients with atrial fibrillation, prosthetic heart valves, or a history of recurrent venous thromboembolism [1] [3]. * **Aspirin (C):** An antiplatelet drug used for the primary and secondary prophylaxis of arterial thrombosis (e.g., Myocardial Infarction and Stroke) [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Heparin Resistance:** If a patient does not show an increase in aPTT despite high doses of heparin, suspect **Antithrombin III deficiency**. * **LMWH vs. UFH:** LMWH (e.g., Enoxaparin) is preferred for prophylaxis due to a longer half-life, better bioavailability, and lower risk of Heparin-Induced Thrombocytopenia (HIT) [4]. * **Antidotes:** Remember **Protamine sulfate** for Heparin and **Vitamin K/FFP** for Warfarin.

Question 229: Which of the following is an antifibrinolytic agent?

A. Dabigatran
B. Protamine
C. Alteplase
D. Epsilon aminocaproic acid (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Epsilon aminocaproic acid** **Mechanism of Action:** Antifibrinolytics are drugs that prevent the breakdown of fibrin clots. **Epsilon aminocaproic acid (EACA)** and **Tranexamic acid** are lysine analogues. They bind to the lysine-binding sites on **plasminogen** and **plasmin**, preventing them from binding to fibrin. This inhibits the activation of plasminogen into plasmin, thereby blocking fibrinolysis (clot dissolution). They are clinically used to control excessive bleeding in conditions like post-prostatectomy, menorrhagia, or fibrinolytic drug overdose. **Analysis of Incorrect Options:** * **A. Dabigatran:** This is a **Direct Thrombin Inhibitor (DTI)**. It is an oral anticoagulant used to prevent strokes in atrial fibrillation and treat DVT/PE. It prevents clot formation rather than inhibiting clot breakdown. * **B. Protamine:** This is a low-molecular-weight protein that acts as a **chemical antagonist to Heparin**. It is used specifically to reverse heparin-induced anticoagulation (e.g., after cardiac surgery). * **C. Alteplase:** This is a **Thrombolytic (Fibrinolytic)** agent. It is a recombinant tissue plasminogen activator (rt-PA) that converts plasminogen to plasmin to actively dissolve existing clots in acute MI or ischemic stroke. It is the functional opposite of an antifibrinolytic. **High-Yield Clinical Pearls for NEET-PG:** * **Tranexamic acid** is approximately 10 times more potent than Epsilon aminocaproic acid. * **Aprotinin** is another antifibrinolytic that works by directly inhibiting plasmin (though its use is restricted due to side effects). * **Side Effect:** A major risk of antifibrinolytics is the development of **thrombosis** (DVT/PE) due to the inhibition of natural clot clearance. * **Specific Reversal Agents:** * Heparin → Protamine Sulfate * Warfarin → Vitamin K / PCC * Dabigatran → Idarucizumab * Rivaroxaban/Apixaban → Andexanet alfa

Question 230: What is the most common adverse effect associated with ticlopidine?

A. Neutropenia
B. Diarrhea (Correct Answer)
C. Hemorrhage
D. Thrombocytopenic purpura

Explanation: **Explanation:** Ticlopidine is a first-generation P2Y12 receptor antagonist (thienopyridine) that inhibits ADP-induced platelet aggregation. **1. Why Diarrhea is the correct answer:** While ticlopidine is notorious for its hematological toxicities, **diarrhea** is statistically the **most common** adverse effect, occurring in approximately 12–20% of patients. It is often dose-dependent and typically occurs within the first few weeks of treatment. Other frequent gastrointestinal disturbances include nausea and dyspepsia. **2. Analysis of Incorrect Options:** * **Neutropenia (Option A):** This is the most **serious** and characteristic side effect, occurring in about 2.4% of patients (severe in 0.8%). Because it can be life-threatening, it requires mandatory CBC monitoring every two weeks for the first three months. However, it is less frequent than diarrhea. * **Hemorrhage (Option C):** While bleeding is a risk with any antiplatelet agent, it is not the most common side effect specific to ticlopidine compared to GI upset. * **Thrombocytopenic Purpura (TTP) (Option D):** Ticlopidine is associated with rare but severe TTP. While high-yield for exams due to its severity, its incidence is very low (approx. 1 in 2,000 to 5,000 patients). **NEET-PG High-Yield Pearls:** * **Mechanism:** Irreversible blockade of P2Y12 (ADP) receptors. * **Clinical Shift:** Ticlopidine has been largely replaced by **Clopidogrel** because clopidogrel has a better safety profile (lower risk of neutropenia and TTP) and fewer GI side effects. * **Monitoring:** If ticlopidine is used, frequent monitoring of WBC counts is essential during the first 90 days. * **Pro-drug:** Like clopidogrel, ticlopidine is a pro-drug requiring hepatic activation.

Practice by Chapter

Hematopoietic Growth Factors

Practice Questions

Iron Preparations and Management of Iron Deficiency

Practice Questions

Vitamin B12 and Folic Acid

Practice Questions

Anticoagulants: Heparins and Direct Inhibitors

Practice Questions

Oral Anticoagulants

Practice Questions

Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Hemostatic Drugs

Practice Questions

Plasma Expanders

Practice Questions

Blood Transfusion and Alternatives

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free